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Calcimimetic agents: Review and perspectives. tal surgical parathyroidectomy every year as a result of
Background. Recognition of the role of the extracellular treatment failure or severe clinical complications [4].
calcium-sensing receptor (CaR) in mineral metabolism has Parathyroid surgery is associated with major risks relatedgreatly improved our understanding of calcium homeostasis.
to anesthesia, pre- and post-surgical complications, in-The activation of this receptor by small changes in the extracel-
duction of permanent hypoparathyroidism, or recur-lular ionized calcium (ec(Ca2)) regulates PTH, calcitonin secre-
tion, urinary calcium excretion, and, ultimately, bone turnover. rence of the secondary hyperparathyroidism. The hypo-
Methods. The cloning of the CaR and the discovery of muta- parathyroid state is associated with low bone remodeling,
tions that make the receptor less or more sensitive to calcium adynamic bone disease, increased serum calcium andhave allowed a better understanding of several hereditary dis-
phosphorus product, vascular calcifications, and the dev-orders characterized by either hyperparathyroidism or hypo-
astating lesions of calciphylaxis [5–7]. Thus, the idealparathyroidism. The CaR, able to amplify the sensitivity of the
CaR to Ca and suppress PTH levels with a resulting decrease treatment would be a drug that could efficiently, safely,
in blood Ca, became an ideal target for the development of and cyclically suppress the secretion of parathyroid hor-
compounds, the calcimimetics. Experience with the calcimi-
mone (PTH) without interfering with the calcium andmetic R-568 in patients with primary and secondary hyperpara-
phosphorus intestinal absorption.thyroidism and parathyroid carcinoma are summarized.
Results. The first clinical studies with the first-generation
Parathyroid cell calcium-sensing receptorcalcimimetic agents have demonstrated their efficacy in low-
ering plasma intact PTH concentration in uremic patients with During the last 25 years, scientists have been interestedsecondary hyperparathyroidism. However, the low bioavail-
in demonstrating that the secretion of PTH is mainlyability of these first calcimimetics predicts a difficult clinical
regulated by a membrane receptor on the parathyroidutilization. The second-generation calcimimetic, AMG 073,
having a better pharmacokinetic profile, appears to be effective cells which is capable of responding to small variations
and safe for the treatment of secondary hyperparathyroidism, in the extracellular ionized calcium (ec(Ca2)) concentra-suppressing PTH levels while simultaneously reducing serum tion. It was only in 1993 that Brown et al [8] cloned thephosphorus levels and the calcium x phosphorus product.
parathyroid cell calcium-sensing receptor (CaR). This isConclusion. The advantage of controlling PTH secretion
a 121-kD protein with three main structural domains, awithout the complications related to hypercalcemia, hyper-
phosphatemia, and increased calcium x phosphorus product is long extracellular N-terminal domain, seven membrane-
very promising. spanning helices, and a hydrophobic intracellular C-ter-
minus characteristic of G-protein coupled receptors. The
CaR belongs to the type III family of structurally unique
More than a century after its identification, secondary G protein-coupled receptors, which includes other CaRs,
hyperparathyroidism remains a problem in more than metabotropic glutamate receptors (mGluR1-8), putative
one third of patients with chronic renal insufficiency pheromone receptors expressed in the rodent vomerona-
[1–3]. Despite the use of new vitamin D analogs and new sal organ (V2Rs), three sweet taste receptors (T1R1-3),
calcium-free, aluminum-free phosphate binders, many and GABAB receptors [9]. The parathyroid and kidney
patients with secondary hyperparathyroidism are not CaRs are 1081 and 1079 amino acid long proteins, respec-
controlled due to vitamin D–associated hypercalcemia tively. The CaR can be considered a low-affinity receptor,
and hyperphosphatemia, or parathyroid gland resistance. responding to relatively high concentration of ec(Ca2),
Three percent to 5% of patients require a total or subto- over one mmol/L. The limited selectivity of the receptor
is responsible for its activation by numerous divalent or
trivalent cations in addition to calcium, such as magne-Key words: calcium-sensing receptor, calcimimetics, secondary hyper-
sium, gadolinium, aluminum, and lanthanum, and byparathyroidism, hypocalcemia, parathyroid hormone, renal osteodys-
trophy, review. other polycationic compounds such as neomycin, sper-
mine, and numerous amino acids [10, 11]. The activation 2003 by the International Society of Nephrology
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Table 1. Agonists and antagonists of the calcium receptorsof the CaR by any one of these agonists results in the
stimulation of the Gi protein, phospholipase C, inositide Agonists
trisphosphate cascade, the mobilization of intracellular Type I calcimimetics Positive charges EC50
Inorganic cationscalcium, and the activation of protein kinase C (PKC).
Calcium 2 1.2 mmolIts activation also inhibits the adenylcyclase signaling
Magnesium 2 5.2 mmol
pathway and protein kinase A (PKA) [8, 12]. Modifica- Lanthanum 3 33 m
Gadolinium 3 20 mtions in these signal transduction pathways result in the
Aluminum 3 4 mmolinhibition of PTH secretion.
Barium 2 —
The physiologic relevance of the cloned CaR in de- Cadmium 2 —
Nickel 2 —termining the level at which circulating ecCa2 is set has
Cobalt 2 —been established by the identification of several inherited
Iron 2 —
diseases due to inactivation or activation mutations in Lead 2 0.1 mmol
Polyaminesthe parathyroid CaR gene, namely familial hypocalciuric
Spermine 3 150 mhypercalcemia, neonatal severe hyperparathyroidism,
Spermidine 4 2.0 mmol
and familial hypercalciuric hypocalcemia [12–14]. Pentaethylenehexamine 6 500 m
Hexacyclin 6 21 m
AminosidesCalcimimetic agents
Streptomycin 3 600 m
After discovery of the CaR there was interest in the Bekanamycin 5 200 m
Gentamycin 5 150 mdevelopment of compounds with the capacity of modu-
Neomycin 6 30 mlating the function of the receptor, thus providing an-
Polybasic amino acids and
other tool for the medical treatment of both primary other peptides
Protamine 21 75 mand secondary hyperparathyroidism (Table 1) [10, 15–
Polylysine (38 kD) 55 3 nmol17]. The first compounds were called “type I calcimimet-
Polyarginine (100 kD) 640 4 nmol
ics” because they mimicked the effects of ecCa2. The Type II calcimimetics
NPS R-467 1 4.8 msecond compounds were called “type II calcimimetics”
NPS S-467 1 70 mbecause they changed the structural conformation of the
NPS R-568 1 0.6 m
CaR and stereo-selectively increased its sensitivity to NPS S-568 1 9.8 m
AMG 073 — 2.8 mecCa2. Type II calcimimetics lose their effect in the ab-
KRN568 — (Cmax) 6.5 ng/mLsence of ecCa2 and do not really mimic the effect of Others
ecCa2; therefore, naming them calcimimetics is probably Thimerosal (merthiolate) — —
Antagonistsinappropriate and they should be called “positive allo-
Calcilyticssteric modulators of CaR.” The third compounds have
NPS 2143 — —
been called “calcilytics” because they inhibit CaR func-
tion and stimulate PTH secretion [10, 17]. It has been
suggested by site-directed mutagenesis studies that the
mode of action of the type II calcimimetics agents may
cemia might be due to the abolition of PTH secretionreside in its binding to the seventh transmembrane do-
with a decrease in bone turnover, and not to the stimula-main of the CaR [18]. Several calcimimetic agents have
tion of the renal CaR [19, 20].already been developed: first-generation compounds, in-
Six heterogeneous studies in uremic animals with sec-cluding NPS R-567, NPS S-567, NPS R-568, NPS S-568,
ondary hyperparathyroidism have been published (Tableand KRN-568, and a second-generation compound, AMG
2). In these studies, NPS R-568 at doses ranging from073.
1.5 to 15 mg/kg/day reduced the proliferation rate of
parathyroid cells by 50%, stopped the progression ofAction of calcimimetic agents in vitro and in animals
parathyroid gland hyperplasia, and corrected the histo-The calcimimetic agents suppress the secretion of PTH
logic signs of high bone turnover [19, 21–25].in a dose-dependent manner in cultured parathyroid cells
and in healthy animals. In animals, oral NPS R-568 pro-
Clinical use of calcimimetic agentsvokes a rapid dose-dependent (ED50, 1.1  0.7 mg/kg)
Calcimimetic agents have been tested in subjects withdecrease in serum PTH and calcium concentrations. At
normal renal function [26, 27]. In one study, 18 post-a dose of 3.3 mg/kg, the maximum effect on PTH levels
menopausal women were randomized into two groups;is reached 15 minutes after administration. At doses
one group received increasing doses of oral NPS R-568ranging from 10 to 100 mg/kg, hypocalcemia is almost
(10 to 400 mg/day), and the other group was treated withimmediate, lasting for more than 24 hours. Studies per-
placebo. The levels of intact PTH decreased by 34%formed in rats submitted to bilateral nephrectomy and
parathyroidectomy suggest that the striking hypocal- from baseline values 30 to 120 minutes after the dose of
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Table 2. Calcimimetics in animals with uremic secondary hyperparathyroidism
Duration
Reference Type of CRF Dose of calcimimetic of treatment Main results
Wada et al [21] Nx. 5/6th 1.5–15 mg/kg/b.i.d. (gavage) 4 days 50% reduction in the proliferation rate of parathyroid cells
Fox et al [19] Nx. 5/6th 5–10 mg/kg/q.i.d. (gavage) 6 hours 82 to 94% reduction in serum PTH levels
Wada et al [22] Renal arterial 30–100 mol/kg/q.i.d. (gavage) 54 days 50% reduction in serum PTH levels
ligation 20 mol/kg/q.i.d. (subcutaneous) 54 days Normalization of serum PTH levels
Chin et al [23] Nx. 5/6th 10–30 mol/kg/q.i.d. (gavage) 8 weeks Stop the progression of secondary hyperparathyroidism
20 mol/kg/q.i.d. (subcutaneous)
Wada et al [24] Nx. 5/6th 3–30 mg/kg/q.i.d. (gavage) 30 days Correction of histologic signs of secondary hyperparathyroidism
Ischii et al [25] Adriamycin 10 mg/kg/q.i.d. (gavage) 8 weeks Restoration of trabecular bone volume; 14% increase in bone
mineral density
Renal arterial 4.5 mg/kg/q.i.d. (subcutaneous) 8 weeks No bone effect
ligation
Nx. is nephrectomy.
10 mg, and decreased by 74% after 400 mg of NPS R-568. PTH levels from 2000 to 3500 pg/mL. This PTH increase
was believed to occur due to progression of the parathy-The duration of PTH suppression was also dose-depen-
dent and lasted approximately 12 hours. Serum PTH roid carcinoma. The patient remained very active, trav-
eled extensively, and had no side effects over a follow-levels decreased even in the presence of a steady decline
in plasma calcium concentration [27]. up of more than 600 days. In addition, all measures
of cardiac, renal, hepatic, hematologic, and pancreaticThe NPS R-568 was also tested in patients with pri-
mary hyperparathyroidism. Twenty postmenopausal function remained stable throughout the period of treat-
ment. Although such observations were made only inwomen were enrolled and randomized into two groups;
one group received a unique dose of NPS R-568 (from one patient, the data showed that R-568 could be given
safely over a prolonged period of time.4 to 160 mg), and the other group received a placebo
[28]. The minimal effective dose of NPS R-568 was 20 Two complete reports were published regarding the
use of NPS R-568 in dialysis patients with secondarymg, resulting in a 26% suppression of the intact PTH
levels. With doses of 80 and 160 mg, serum PTH fell by hyperparathyroidism. The first study [30] was a small,
two-day study in seven patients with mild hyperparathy-42% and 51%, respectively. The lowest serum intact
PTH levels were observed two hours after the adminis- roidism. Doses of 40 or 80 mg caused PTH levels to fall
by more than 30% after the first dose in 5 of 7 patients,tration of either 80 or 160 mg of NPS R-568, and they
returned to the initial baseline values four and eight and more than 60% after the second dose in 6 of 7
patients. With doses of 120 and 200 mg, PTH was reducedhours after the administration of 80 and 160 mg, respec-
tively. Serum ionized calcium decreased slightly from by more than 60% after the first dose in 6 of 7 patients.
After 24 hours, the pretreatment PTH level was still1.35 to 1.30 mmol/L four hours after the dose of 160 mg.
Similarly, the urinary excretion of calcium increased by 50% lower than the initial basal value; nonetheless, PTH
fell 50% or more after the second dose in 6 of 7 patients.a factor of 2.3 only two hours after the administration
of 160 mg of NPS R-568 and returned to baseline values Blood Ca was not significantly changed after the low
dose, but fell significantly after the high dose. Serumeight hours later.
The calcimimetic agent, R-568, was given to a patient calcitonin levels doubled four hours after the high doses
and returned to baseline 48 hours later. The second studywith inoperable parathyroid carcinoma who presented
with hypercalcemia (blood Ca 1.96 mmol/L), high [16] was performed in 21 hemodialysis patients with mod-
erate secondary hyperparathyroidism (PTH between 300PTH levels (1128 pg/mL), and altered mental status;
hypercalcemia failed to respond to intravenous saline and 1200 pg/mL). They were randomized into two groups:
5 patients received a placebo and 16 patients receivedand furosemide, several doses of intravenous pamidro-
nate, and salmon calcitonin over 18 days [29]. The calci- an oral dose of 100 mg per day of NPS R-568 for 15
days. In the treated group, the serum level of PTH fellmimetic was initiated at 200 mg/day and subsequently
increased to 400 mg/day. The patient’s symptoms im- by 66%, 78%, and 70% after one, two, and four hours,
respectively, and remained significantly lower than theproved after three days of R-568 treatment and the pa-
tient was discharged home after 28 days of treatment basal values during the next 24 hours. Despite lower
ionized calcium concentrations, predose intact PTH lev-with a blood Ca of 1.53 mmol/L and a PTH level of
357 pg/mL. Treatment with the calcimimetic was contin- els decreased progressively over the first nine days of
treatment with R-568. Levels remained below pretreat-ued and the dose was titrated up to 600 mg/day; this
treatment maintained the total serum calcium between ment levels for the duration of the study, in contrast
with the placebo treated group. Serum total and blood2.75 to 3.0 mmol/L, despite the progressive increase in
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ionized calcium levels decreased from pretreatment lev- was 625  310 pg/mL (mean  SE) for the 36 patients
els in patients given R-568, whereas values were un- treated with AMG 073 and 582  421 pg/mL for the
changed in those given a placebo. Blood ionized calcium placebo-treated patients. The intact PTH levels de-
levels fell below 1.0 mmol/L in seven of 16 patients re- creased by 32.5% from the baseline during the mainte-
ceiving R-568; five patients withdrew from the study nance phase in the AMG 073 group and increased by
after developing symptoms of hypocalcemia, while three 3.0% in the placebo-treated patients. In the AMG 073
patients completed treatment after the R-568 dose was group the calcium x phosphorus product at the end of
reduced. An interesting point of this study is the pharma- the maintenance period was decreased by 7.9% from the
cokinetic data of NPS R-568. After a single dose, its baseline value, compared to an increase of 11.0% in the
maximal plasma concentration was obtained after a vari- placebo-treated group. The serum phosphorus was also
able lapse of time, ranging from 1 to 24 hours. The peak reduced by 2.6% in the AMG 073 treated patients and
plasma concentration, often observed between 2.5 and the mean serum calcium level was reduced by 4.6% from
4.4 hours, greatly differed from one patient to another baseline, although the absolute serum calcium level re-
(from 0.42 to 42.2 ng/mL). The bioavailability of NPS mained within the normal range.
R-568 appears to be very low (1%), which suggests The potential of the second-generation calcimimetic
that manipulation of this first-generation calcimimetic for treatment of secondary hyperparathyroidism in he-
would be difficult. modialysis patients has been shown in the combined
Due to the pharmacokinetic profile and interactions results of three, 12-week, randomized, double-blind, pla-
with other drugs, the development of R-568 was discon- cebo-controlled, dose titration trials (abstract; Drueke
tinued and a second-generation calcimimetic agent, AMG et al, J Am Soc Nephrol 12:764A, 2001). Two hundred
073, developed. In the initial clinical trials, AMG 073 and fifteen hemodialysis patients (141 AMG 073 treated
showed the potential to treat hemodialysis patients with and 74 placebo treated) with serum intact PTH levels
secondary hyperparathyroidism with promising results.
300 pg/mL, calcium levels between 8.8 mg/dL and 11.0
A randomized, double-blind, placebo-controlled, multi- mg/dL, and a calcium x phosphorus product less than
center study was conducted in hemodialysis patients with
70, were evaluated. AMG-073 was titrated up to 50 mg/
secondary hyperparathyroidism and six sequential single
day in two studies, and 100 mg/day in one study, baseddoses were administered (5, 10, 25, 50, 75, and 100 mg
upon PTH levels and safety profile. Mean serum PTHof AMG 073 or placebo) [31]. Doses of 25, 50, 75, and
levels was reduced by 20% to 33% in the AMG 073 group100 mg caused a dose-dependent decrease in plasma
and increased by 16% in the placebo group. Eighty-threeintact PTH with a maximum suppression observed be-
percent of AMG 073 patients had a reduction in serumtween two and four hours after administration, followed
PTH levels of more than 30% at the end of 12 weeks.by a slow recovery of the intact PTH during the subse-
Mean serum calcium x phosphorus product decreasedquent hours but remaining below the baseline values
by 8% in the AMG 073 group and increased by 14% inafter 24 hours. Single doses of 75 and 100 mg of AMG 073
the placebo group. No major side effects were reported.reduced serum calcium by 8.3% and 9.4%, respectively.
Another randomized, placebo-controlled, double-blind,Following these results daily, fixed doses of 10, 25, and 50
12-week trial evaluated AMG 073 at doses up to 180 mgmg of AMG 073 were administered for eight consecutive
in 82 hemodialysis patients (abstract; Block et al, J Amdays in hemodialysis patients with plasma intact iPTH
Soc Nephrol 13:572A, 2002). These patients had PTH250 pg/mL and 1500 pg/mL [31]. Doses of 25 and 50
levels 300 pg/mL, despite standard therapy with phos-mg were associated with decreases in iPTH concentra-
phate binders and vitamin D. The mean PTH levels de-tions. The 50 mg dose was associated with a decrease in
creased by 47% from baseline in the active drug group,mean serum calcium levels. On day eight, serum phos-
and the target PTH level was achieved in 54% of thephorus levels and the calcium x phosphorus product were
patients not controlled on current therapy. Percent ofreduced from baseline levels in all treatment groups re-
reductions in calcium and phosphorus product in patientsceiving AMG 073.
The efficacy and safety of AMG 073 was shown in receiving AMG 073 were of similar magnitude to that
a double-blind, placebo-controlled, 18-week study with observed in previous studies. The incidence of adverse
dose titration during the first 12 weeks using daily doses events was similar in the two treatment groups.
of 10, 20, 30, 40, and 50 mg AMG 073 or placebo (ab-
stract; Lindberg et al, J Am Soc Nephrol 11:578A, 2000).
CONCLUSIONBecause of the good safety profile observed in the previ-
After the cloning of the CaR and the developmentous study, doses of AMG 073 were titrated up to 100
of positive allosteric modulators of CaR, the medicalmg per day in another study (abstract; Quarles et al, J Am
treatment of several hyperfunctioning and/or hypofunc-Soc Nephrol 12:773A, 2001). Seventy-one hemodialysis
patients were evaluated. The baseline intact PTH value tioning parathyroid glands states seems to be devoted
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Table 3. Potential medical uses of calcium receptor modulators may be very useful for the treatment of primary and
secondary hyperparathyroidism, parathyroid carcinoma,Parathyroids
Inherited parathyroid disorders and probably a few other rare disorders, such as para-
Primary hyperparathyroidism thyromatosis and calciphylaxis.Secondary hyperparathyroidism
Parathyroid carcinomatosis
Reprint requests to Dr. Pablo Uren˜a, Service de Ne´phrologie et Dia-Surgical parathyroidectomy failure
lyse, Clinique de l’Orangerie, 11 boulevard Anatole France, 93300 Aub-Ectopic parathyroid gland localization
ervilliers, France.Parathyromatosis
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